Decibel Therapeutics
BOSTON, MA · Founded 2013 · CIK 0001656536 · Biotech · Acquired
Gene therapy for genetic hearing loss
decibeltx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $63M
- 2 Form D · Nov 2020
- 71 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 12 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $8,000,000 | |
| Private capital raised | Form D · SEC | $54,800,067 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2333 | NEMAGEN DISCOVERIES INC | — | — |
| 2334 | NEMAMETRIX, INC | — | $9.4M |
| 2335 | TERAIMMUNE, INC. | — | $3.0M |
| 2336 | Decibel Therapeutics | — | $63M |
| 2337 | 3P BIOTECHNOLOGIES, INC. | — | — |
| 2338 | Mythic Therapeutics | — | $53M |
| 2339 | DEEPSEQAI LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Troy BrennanDirector
- Roger BrownDirector
- Jens EcksteinDirector
- Neil ExterDirector
- Steven HoltzmanDirector · Executive Officer
- Jeffrey JonasDirector
- John KeiltyExecutive Officer
- Elisabeth LeidermanExecutive Officer
- Craig MuirDirector
- Anthony PhilippakisDirector
- Christine PoonDirector
- Laurence ReidDirector · Executive Officer
- George ScangosDirector
- Michael SolomonExecutive Officer
- Kevin StarrDirector · Executive Officer
- Peter ThompsonDirector
Patents
- Compositions And Methods For Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systemsgranted
- Cochlear Inner Hair Cell Promoters And Uses Thereofapplication
- AAV1 Vectors And Uses Thereof For Treatment Of Otic Indicationsapplication
- Methods Of Otoprotection Against Platinum-based Antineoplastic Agentsgranted
- Cochlear Inner Hair Cell Promoters And Uses Thereofgranted
- SLC26A4 Regulatory Elements And Uses Thereofapplication
- AAV1 Vectors And Uses Thereof For Treatment Of Otic Indicationsgranted
- Hypertonic Pharmaceutical Compositions Containing An Anti-platinum Chemoprotectant Agentapplication
- Myosin 15 Promoters And Uses Thereofapplication
- Compositions And Methods For Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systemsapplication
- Myosin 15 Promoters And Uses Thereofgranted
- Hypertonic Pharmaceutical Compositions Containing An Anti-platinum Chemoprotectant Agentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.